Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지

Childhood cutaneous leishmaniasis: report of 117 cases from Iran

  • Talari Safar Ali (Department of Parasitology, Kashan University of Medical Sciences) ;
  • Talaei Rezvan (Department of Parasitology, Kashan University of Medical Sciences) ;
  • Shajari Cholamreza (Department of Parasitology, Kashan University of Medical Sciences) ;
  • Vakili Zarichehr (Department of Parasitology, Kashan University of Medical Sciences) ;
  • Taghaviardakani Abbas (Department of Parasitology, Kashan University of Medical Sciences)
  • Published : 2006.12.10
Download PDF
⟨ Previous Next ⟩

Abstract

Cutaneous leishmaniasis (CL), due to Leishmania major, is endemic in different parts of Iran and has long been recognized in most provinces of Iran. This study was conducted to determine the prevalence of childhood leishmaniasis in 3 areas at the southeast of Kashan, A descriptive study was carried out on all children referred to central laboratories during a 3-year period. Initial information including age, sex, sites of ulcer on the body, number of lesions, address, and the place of the disease was obtained. The study gathered 117 children, and the results showed a prevalence of 7.2% in patients with lesions among the population and 4.2% of people displayed lesion and scar. The ages of subjects were from 6 to 15 years (average 9.75 years). The boy: girl ratio was 1.2. All of our patients lived in an endemic area. The face was affected in 47.0% of cases. The encountered forms of leishmaniasis are as follows: papulonodular 27.4%, ulcer 60.7%, sporotrichoid 6%, impetiginous 2.5%, and erysipeloid 3.4%. Treatment with intramuscular meglumine antimoniate 20-30 mg/kg/day was done for 93 patients. Meglumine antimoniate treatment was tolerated with no side effects. All leishmaniasis lesions healed within an average period of 2-14 months. Hyperpigmented scars were formed in 25.6% of the patients, atrophic scars in 4.3%, and hypopigmented scars were in 3.4%, respectively The findings of this study indicate increased prevalence of CL in the villages at the area of Kashan and Aran-Bidgol. The clinical finding patterns belonged to different endemic strains of L. major in Isfahan, which indicates the possible transmission of infection from Isfahan to this area.

Keywords

References

  1. Ahmadiyazdi C, Narmani MR, Sadri B (2004) Cutaneous leishmaniasis in Iran. Int J Infect Dis 12: 1-9 https://doi.org/10.1016/S1201-9712(07)00222-6
  2. Ajdary S, Alimphammadian MH, Kharazimi A (2000) Comparsion of immune profile of non healing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 68: 1760-64 https://doi.org/10.1128/IAI.68.4.1760-1764.2000
  3. Alimohammadian MH, Almasi H, Khabiri AR, Hatam G, Amirkhani A (1999) Identification of species and characteristics of an outbreak of cutaneous leishmaniasis in a new focus of Iran. Iranian Biomed J 3: 31-39
  4. Berman JD (1997) Human leishmaniasis: Clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24: 684-703 https://doi.org/10.1093/clind/24.4.684
  5. Edrissian GH, Zoevein Z, Nadim A (1982) A simple tecchnique for preparation of smears from the ear of Rhombomys opimus for the detection of leishmanial infection. Trans R Soc Trop Med Hyg 76: 706-707
  6. Hanafi AA, Dehghani A, Jafari R, Ehrampoosh MH (2002) Efficacy of control program of zoonotic cutaneous leishmaniasis in a new focus of the disease. Med J Mashhad University of Medical Sciences 46: 80-87
  7. Herwaldt BL (1999) Leishmaniasis. Lancet 354: 1339-64
  8. Javadian E, Nadim A, Tahvildari A, Assefi V (1967) Epidemiology of cutaneous leishmaniasis in Korassan Iran. Bull Soc Path Exot 69: 140-143
  9. Kafetzis DA (2003) An overview of pediatric leishmaniasis. J Postgrad Med 49: 31-8 https://doi.org/10.4103/0022-3859.930
  10. Kharfi M, Benmously R, Fekih N, Daoud M, Kamoun MR (2004) Childhood leishmaniasis : Report of 106 cases. Dermatol Online J 10: 1-7
  11. Khoury S, Saliba EK, Oumeish OY, Tawfig MR (1996) Epidemiology of cutaneous leishmaniasis in Jordan. Int J Dermatol 35: 566-559 https://doi.org/10.1111/j.1365-4362.1996.tb03656.x
  12. Markele WH, Khaldoun MMO (2004) Cutaneous leishmaniasis: recognition and treatment. American Family Physician, pp.1-9
  13. Moaddeb A, Gettner S, and Ardehali S (1993) Studies on the causative agent of cutaneous leishmaniasis in Shiraz Iran. Iran J Med Sci 18: 28-33
  14. Momeni A (1994) Clinical picture of cutaneous leishmaniasis in Isfahan, Iran. Int J Dermatol 33: 260-5 https://doi.org/10.1111/j.1365-4362.1994.tb01039.x
  15. Nadim A, Faghih MA (1968) The epidemiology of cutaneous leishmaniasis in Isfahan province of Iran. Trans R Soc Trop Med Hyg 62: 534-542 https://doi.org/10.1016/0035-9203(68)90140-5
  16. Nadim A, Seyedi RMA (1971) A brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Med Iran 8: 99-106
  17. Ozbel Y, Turgay N, Ozensoy S, Ozbilgin A, Alkan MZ (1995) Epidemiology, diagnosis and control of leishmaniasis in the Mediterranean region. Ann Trop Med Parasitol 89: 89-93
  18. Sadr F, Talari SA (1998) Effect of glucantime on electrocardiogram of patients suffering from cutaneous leishmaniasis. Feyz, Kashan University of Medical Sciences 5: 13-20
  19. Salimi M (2000) A clinical and epidemiological comparison on the cutaneous leishmaniasis in the city and villages of Isfahan. Iran J Public Health 2: 214-219
  20. Selim MM, Vlasin Z, Jaroskova L (1990) Leishmaniasis, currently recommended treatment. Int J Dermatol 29: 318-21 https://doi.org/10.1111/j.1365-4362.1990.tb04750.x
  21. Talari SA, Sadr F (2005) Treatment of cutaneous leishmaniasis: effectiveness, and adverse effects of the drugs. Feyz, Kashan University of Medical Sciences 33: 85-94
  22. Talari SA, Vakili Z, Emami AH (1999) Effect of glucantime on blood parameters in patients with cutaneous leishmaniasis. Feyz, Kashan University of Medical Sciences 10: 17-22
  23. World Health Organization (1984) Expert committee: the leishmaniasis. WHO Tech Rep Ser No. 701: 2-4
  24. World Health Organization (1990) Expert committee: epidemiological aspects. In: Control of the leishmaniasis. WHO Tech Rep Ser No. 793: 41-46
  25. Yaghoobi MR, Akhavan AA, Zahrai AR (2003) Epidemiological study in a new focus of cutaneous leishmaniasis in the Islamic Republic of Iran. East Mediter Health J 9: 65-72
  26. Yaghoobi MR, Hanafi AA, Akhavan AA, Zahrai AR, Mohebali M (2001) Epidemiological study in a new focus of cutaneous leishmaniasis due to Leishmania major in Ardestantown, central Iran. Acta Trop 79: 115-121 https://doi.org/10.1016/S0001-706X(01)00085-7
  27. Yaghoobi MR, Hanafi AA, Javadian E, Mohebali M (2002) A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med J 23: 291-294
  28. Yaghoobi MR, Jafari R, Hanafi AA (2004) A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann Saudi Med 24: 98-101 https://doi.org/10.5144/0256-4947.2004.98